Industry defenders will argue, “but Revlimid has competition.” Here’s
@DavidP4AD explaining why that’s not actually true.
Revlimid is a cancer treatment that is marketed by Bristol Myers Squibb. It carries a list price of over $18,000 per cycle (given every 28 days).
We investigated the patenting strategies around Revlimid. Here's what we found:
đź“„206 patent applications have been filed
đź“„117 patents have been granted
These granted patents amount to 42.9 years of patent protection, approximately 2X the 20-year limit intended by the U.S. patent system. They have been used to block unlimited generic entry until January 2026, providing up to nearly 6 years of extra market exclusivity.